Early access
Sign in
Taking people in United StatesPhase 3

a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers

Key facts

Who runs it
Applied Biologics, LLC
Where
Boardman, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
253 people, planned
Started
8 Oct 2026
Expected to end
Sept 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Standard of Care
  • BIOxHEAL (human amniotic membrane allograft)
Record updated
16 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Participants must be at least 18 years of age or older. Participants must have a diagnosis of type 1 or 2 diabetes mellitus. At randomization (or enrollment for the sentinel cohort), participants must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 25.0 cm2 measured post debridement
  • The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit
  • The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus
  • The target ulcer must be Wagner Grade 1 extending at least through the dermis or subcutaneous tissue
  • The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
  • ABI greater than or equal to 0.7 and less than or equal to 1.3 TBI greater than or equal to 0.6 TCOM greater than or equal to 40 mmHg Arterial Doppler ultrasound with biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle on the extremity where the index ulcer is located If the participant has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer
  • The participant must consent to using the prescribed offloading method for the duration of the study
  • The participant must agree to attend the weekly study visits required by the protocol
  • The participant must be willing and able to participate in the informed consent process
  • The participant must have a suitable living environment to manage prescribed offloading and wound care management

Who cannot take part

  • Receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy
  • Previous partial amputation on the affected foot, if the resulting deformity impedes proper offloading of the target ulcer
  • Treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit
  • Known life expectancy of less than 6 months. Target ulcer is not secondary to diabetes. Wagner Grade 2 to 5 ulcers. Target ulcer is infected, or there is cellulitis in the surrounding skin
  • Evidence of osteomyelitis complicating the target ulcer, based on clinical assessment supported by at least one of the following:
  • Imaging (for example, plain radiography, MRI, or nuclear medicine study) consistent with osteomyelitis Positive bone culture Abnormal inflammatory markers (for example, ESR, CRP) in conjunction with clinical signs highly suggestive of osteomyelitis per Investigator judgment - Documentation of the basis for diagnosing or excluding osteomyelitis must be available in the participant's source documents Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy
  • Topical application of steroids to the ulcer surface within one month of initial screening
  • The surface area of the target ulcer has reduced in size by more than 40% between Screening Visit 1 and Treatment Visit 1 during the protocol-defined screening period
  • Acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer
  • A medical or psychological condition that, in the opinion of the investigator, may interfere with study assessments
  • Glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit
  • End stage renal disease requiring dialysis. Serum creatinine level greater than 3.0 mg/dL. Aspartate aminotransferase (AST, GOT) and/or alanine aminotransferase (ALT, GPT) greater than 3 times the upper limit of normal
  • Women who are pregnant or considering becoming pregnant within the next 6 months
  • Male or female participants who are unwilling or unable to comply with the required contraceptive measures for the duration of study participation
  • Mini Nutritional Assessment (MNA) screening score below 12

Where in United States

  • NOMS Ankle and Foot Care CenterBoardman, United StatesContact: Lawrence DiDomenico, DPMTaking people

About the trial

What the trial wants to find out

BIOxHEAL is an investigational placental-derived biologic being evaluated for the treatment of nonhealing diabetic foot ulcers. Adults with type 1 or type 2 diabetes who have a diabetic foot ulcer that has not healed with standard wound care may be eligible to participate. Participants in the randomized phase are assigned by chance in a 2:1 ratio to receive either BIOxHEAL administered topically in combination with standard of care (SOC), or SOC alone. Treatment is administered once weekly for up to 12 weeks or until complete ulcer closure. The primary objective is to evaluate whether BIOxHEAL plus SOC increases the proportion of target ulcers achieving complete closure at Week 12 compared with SOC alone.

The 3 groups in the trial

  • Sentinel Cohort: BIOxHEAL + SOCTreatment being tested

    Non-randomized sentinel cohort (5 completed participants required, up to 10 enrolled). Participants receive BIOxHEAL administered topically once weekly plus SOC for up to 12 weeks or until complete ulcer closure, to assess early safety before the randomized phase.

    Treatment: Standard of Care and BIOxHEAL (human amniotic membrane allograft)

  • Randomized: SOC AloneExisting treatment, for comparison

    Participants randomized 2:1 to receive protocol-defined SOC alone, with weekly treatment visits for up to 12 weeks or until complete ulcer closure, with closure confirmed approximately 2 weeks later.

    Treatment: Standard of Care

  • Randomized: BIOxHEAL + SOCTreatment being tested

    Participants randomized 2:1 to receive BIOxHEAL administered topically once weekly plus SOC for up to 12 weeks or until complete ulcer closure, with closure confirmed approximately 2 weeks later.

    Treatment: BIOxHEAL (human amniotic membrane allograft)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
a Randomized Controlled Multicenter Clinical Trial, Evaluating the Efficacy of a Single Layer Placental-based Biologic and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers.
Record updated
16 October 2026